The NCI solicits applications to establish a collaborative Glioblastoma Therapeutics Network focused on developing novel agents that can cross the blood-brain barrier and testing them clinically in adult GBM patients. The program uniquely spans the gap from late pre-clinical development through IND-enabling studies into Phase 0/1 clinical trials, covering both novel agents and repurposed therapies.
Eligibility Criteria:
Applicants must:
- Be at a U.S. or eligible institution (academic, nonprofit, for-profit, tribal, or government entity)
- Propose a multi-institutional team (≥2 institutions) capable of independently accruing GBM patients to clinical trials
- Include an Administrative Core, ≥2 Research Projects, and ≥1 Shared Resources Core in the U19 multi-project application
- Have capacity to drive therapeutic agents from pre-clinical development through IND to pilot clinical studies
Funding Details:
- Mechanism: U19 Cooperative Agreement (multi-project, clinical trial required)
- Estimated funding: Not specified per award; historically GTN U19s range from ~$500K–$5M+ total costs
- Duration: Multi-year (anticipated project start March 2027)
- Indirect costs: Per NIH institutional negotiated rate
Deadline:
- LOI due: ~30 days prior to application deadline (per standard NIH RFA policy)
- Full application due: May 27, 2026
Where to go for further information:
- Grants.gov opportunity listing
- NCI GTN Program Page
- Contact: Suzanne Forry, Ph.D. — forryscs@mail.nih.gov